Biosimilar Antibodies

Validated for Therapeutic Research

Functional-grade biosimilars for in vitro and in vivo experiments, validated to support innovation in drug discovery, molecular biology, and cell-based assays!

ISO13485 certified

Up to ≥ 98% purity

cGMP mAbs

In vitro & In vivo mAbs

QC at every step of production

240+ Biosimilars

Our Biosimilar Range

VivoGenie Biosimilars
Low Endotoxin for in vivo studies
Reference Biosimilars
In vitro investigations & comparison studies
Conjugated Biosimilars
Labeled with different dyes or enzymes
Popular Biosimilars
4-1BB CD123 CD37 CD70 ICOS PD-1
AXL CD138 CD38 CEACAM5 IL-17RA PD-L1
B7-H3 CD20 CD40 CS1 IL-2RA TIGIT
BAFF CD22 CD40L CTLA-4 IL-6 TIM3
BAFFR CD27 CD45 EGFR IL-6R TNFRSF10B
BCMA CD30 CD47 EPHA3 MSLN Trop2
CA9 CD33 CD52 GPRC5D NKG2D TweakR

Why choose Biosimilar Antibodies?

Cost-effective and reliable alternatives to reference biologics.
Validated for diverse applications, including ELISAs, flow cytometry, and Western blotting.
Suitable for biophysical characterization (SPR) and immunohistochemistry (IHC).
Proven functionality in blocking, neutralization, co-stimulation, and depletion assays.

Testimonials & Partners

"I ordered from AssayGenie for the first time and would like to share my satisfied impression. The article (Bevacizumab; IVMB0232) was used as a positive control and works excellently in Biacore SPR measurements and VEGF bioassay"

- G. Carsten, Fraunhofer (2024)

Fast-Delivery

Delivery in 7-10 business days

Tech-Support

24 hours on LiveChat & PhD level support

Savings

Cost-effective alternative to therapeutic mAbs

Lot-to-lot Consistency

Ensuring reproducible results

cGMP & ISO Certification

Quality is at the core of everything we do.

Manufactured in state-of-the-art facilities, our products meet the highest standards, including current Good Manufacturing Practicies) cGMP, ISO 9001:2015, and ISO 13485:2016 certifications. These ensure consistent quality, customer-focused innovation, and reliable performance in every batch.

Biosimilar Production

Assay Genie's Biosimilar Development Pipeline creates research-grade biosimilars. We select and characterize reference biologics, then design and express them in host cells. Precise purification yields high-quality antibodies. Rigorous quality control validates structural integrity and functionality. This process ensures reliable biosimilar solutions for research.

Biosimilar Antibody Product Data

VivoGenie Biosimilars

Our VivoGenie Biosimilars are designed to meet the highest quality standards for research and preclinical applications. Featuring exceptional purity (≥95%) validated by SDS-PAGE, our biosimilars ensure reliable performance in WB, FC, and ELISA assays.

https://media.zenobuilder.com/upload/h68l9z2lnx/image-2--45578890.png

VivoGenie Biosimilars

With low endotoxin levels (≤1.0 EU/mg) and minimal aggregation (≥95% monomer verified by SEC), they are ideal for sensitive applications. Formulated in sterile PBS (pH 7.2) without preservatives, stabilizers, or carrier proteins.

Reference Biosimilars

Our Reference & Conjugated Biosimilars demonstrate exceptional performance in research assays. The ELISA assay on the left highlights a dose-dependent response using 0.2 µg of human TNF-α per well, confirming strong binding activity and neutralizing capabilities of the biosimilar.

Conjugated Biosimilars

The flow cytometry data on the right showcases precise binding to target cells, with clear separation between negative and positive populations, ensuring reliable results for functional studies.

Meet Some of the Genie Team!

At Assay Genie, we're here to help every step of the way. Whether you need guidance choosing the right product, updates on your order, or expert support after your purchase, we've got you covered.

Colm PhD, CEO
Sean PhD, CSO
Shane MSc, Sales Manager
Beatriz, Logistics
David PhD, Partner Manager
Marina PhD, Tech Support
Joe MSc, Sales
Miren PhD, Product Manager
Chris PhD, Development Manager
Zac MSc, Operations Manager
Natalia PhD, Tech Support
José MSc, Development Manager

FAQs & Citations

1.) What are research-grade biosimilars?

Research-grade biosimilars are laboratory-produced proteins that are designed to mimic the structure and function of approved biologic drugs. They are used in preclinical studies, assay development, and other non-clinical applications.

2.) How do research-grade biosimilars differ from therapeutic biosimilars?

Research-grade biosimilars are intended for laboratory and research purposes only. They are not subject to the same regulatory scrutiny as therapeutic biosimilars, which must undergo clinical trials and approval processes for patient use.

3.) Are research-grade biosimilars the same as reference biologics?

No, research-grade biosimilars are designed to be similar in structure and function to reference biologics but are not identical. They are primarily used for assay development, drug screening, and in vitro/in vivo research.

4.) Are research-grade biosimilars produced using the same expression systems as the original biologics?

They may be produced in similar systems (e.g., CHO cells, E. coli, yeast), but there can be differences in post-translational modifications, glycosylation patterns, or impurities.

5.) How is the quality of research-grade biosimilars ensured?

Quality is assessed through purity analysis (SDS-PAGE, HPLC, Mass Spectrometry), bioactivity assays, and binding affinity tests (e.g., ELISA, SPR, BLI).

6.) What are common applications of research-grade biosimilars?

- Preclinical drug screening

- Assay development and validation (e.g., ELISA, Western Blot, Flow Cytometry)

- Mechanism of action studies

- Comparative studies against reference biologics

7.) Can research-grade biosimilars be used in animal studies?

Yes, they can be used in in vivo models to study pharmacokinetics, pharmacodynamics, and efficacy before moving to clinical-grade biosimilars.

In Vivo Citations

Product	Author	Citation
PD-1 (CD279) [RMP1-14] In Vivo Antibody (IVMB0038)	Bikoriman et al.	Local Delivery of Accutox® Synergises With Immune-checkpoint Inhibitors at Disrupting Tumor Growth
PD-1 Antibody [RMP1-14] In Vivo Antibody (IVMB0037)	Leane et al.	PD-1 regulation of pathogenic IL-17-secreting γδ T cells in experimental autoimmune encephalomyelitis
IgG Isotype Control (IVMB0183)	Rohani et al.	Tramadol Influences Cellular Metabolism and Autophagy in Germ and Sertoli Cells; Exercise Training as A Potential Ameliorative Strategy
CD25 In Vivo Antibody (IVMB0148)	Calvo et al.	Correlation between systemic allergen desensitisation and long-term asthma protection in mice following intravenous administration of the live tuberculosis vaccine MTBVAC
PD-1 [RMP1-14] In Vivo Antibody (IVMB0037), CD8a (Ly 2.2) In Vivo Antibody (IVMB0070), NK1.1 In Vivo Antibody (IVMB0100), IgG2a Isotype Control (IVMB0188), IgG2b Isotype Control (IVMB0190)	Turley et al.	Intratumoral delivery of the chitin-derived C100 adjuvant promotes robust STING, IFNAR, and CD8+ T cell-dependent anti-tumor immunity
IFNAR-1 In Vivo Antibody (IVMB0202)	Wang et al.	Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice.

Biosimilar Resources - Blogs & Podcast Episodes

Enavatuzumab: Revolutionizing Cancer Research Through Novel Therapeutics
Quick Facts About EnavatuzumabWhat is Enavatuzumab?Enavatuzumab is a monoclonal antibody targeting the TWEAK receptor (Fn14), pivotal in tumor growth and immune regulation.What is the mechanism of action for Enavatuzumab?Enavatuzumab binds to Fn14, inhibiting signaling pathways that promote tumor cell proliferation and survival while [...]
Enavatuzumab: Revolutionizing Cancer Research Through Novel Therapeutics
Quick Facts About EnavatuzumabWhat is Enavatuzumab?Enavatuzumab is a monoclonal antibody targeting the TWEAK receptor (Fn14), pivotal in tumor growth and immune regulation.What is the mechanism of action for Enavatuzumab?Enavatuzumab binds to Fn14, inhibiting signaling pathways that promote tumor cell proliferation and survival while [...]
Siltuximab: Exploring IL-6 Inhibition in Castleman’s Disease and Research
Quick Facts About SiltuximabWhat is Siltuximab?Siltuximab is a monoclonal antibody targeting interleukin-6 (IL-6), a cytokine involved in inflammation and immune regulation.What is the mechanism of action for Siltuximab?Siltuximab binds to IL-6, preventing it from interacting with its receptor and mitigating downstream pro-inflammatory signaling.What [...]

Biosimilar Antibodies